Search Within

Sarcoma Service

Formats
  1. Journal Article (455)
  2. Meeting Abstract (431)
  3. Review (29)
  4. Editorial (9)
  5. Guidelines (8)
  6. Book Section (6)
  7. Miscellaneous (6)
  8. Research Letter (6)
  9. Correspondence (2)
  10. Book Whole (1)
Groups
  1. Department of Medicine (953)
  2. Solid Tumor Oncology Division (953)
  3. GSK Faculty (343)
  4. Tow Center for Developmental Oncology (TCDO) (310)
  5. Hematologic Malignancies, Division of (295)
  6. Department of Pathology and Laboratory Medicine (241)

More Groups

People
  1. William Tap (382)
  2. Sandra D'Angelo (256)
  3. Mrinal Gounder (232)
  4. Ping Chi (177)
  5. Mark Dickson (173)
  6. Cristina Antonescu (138)

More People

Years
  1. 2025 (44)
  2. 2024 (87)
  3. 2023 (79)
  4. 2022 (116)
  5. 2021 (76)
  6. 2020 (90)

More Years

Publications
  1. Journal of Clinical Oncology (274)
  2. Annals of Oncology (70)
  3. Clinical Cancer Research (61)
  4. Cancer Research (31)
  5. Journal for ImmunoTherapy of Cancer (28)
  6. Cancer (19)

More Publications

Publishers
  1. American Society of Clinical Oncology (288)
  2. American Association for Cancer Research (108)
  3. Oxford University Press (92)
  4. Elsevier Inc. (57)
  5. Nature Publishing Group (42)
  6. Springer (40)

More Publishers

Results (953)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Case report: Response to regional melphalan via limb infusion and systemic PD1 blockade in recurrent myxofibrosarcoma: A report of 2 cases
    Journal Article

    Bartlett, E. K.; D’Angelo, S. P.; Kelly, C. M.; Siegelbaum, R. H.; Fisher, C.; Antonescu, C. R.; Ariyan, C. E.
    Frontiers in Oncology (2021)

    Fulltext@MSK | Save
  • Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT)
    Meeting Abstract

    Gelderblom, H.; Abdul Razak, A. R.; Sánchez-Gastaldo, A.; Rutkowski, P.; Wilky, B.; Wagner, A.; van de Sande, M.; Michenzie, M.; Vallee, M.; Sharma, M.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study
    Meeting Abstract

    von Mehren, M.; Heinrich, C.; George, S.; Zalcberg, J. R.; Bauer, S.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A phase Ia/Ib, dose-escalation/expansion study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma
    Meeting Abstract

    Gounder, M.; Patel, M. R.; Yamamoto, N.; Bauer, T. M.; Laurie, S.; Perez-Pitarch, A.; Geng, J.; Cheng, J.; Lahmar, M.; Lorusso, P.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Biomarkers of response and hyperprogression in patients with sarcoma treated with checkpoint blockade
    Meeting Abstract

    Klemen, N. D.; Hwang, S.; Bradic, M.; Rosenbaum, E.; Dickson, M.; Gounder, M.; Kelly, C. M.; Keohan, M. L.; Movva, S.; Thornton, K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Phase I study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma
    Meeting Abstract

    Janku, F.; Bauer, S.; Shoumariyeh, K.; Jones, R. L.; Spreafico, A.; Jennings, J.; Psoinos, C.; Meade, J.; Ruiz-Soto, R.; Chi, P.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • The impact of MYC gene amplification on the clinicopathological features and prognosis of radiation-associated angiosarcomas of the breast
    Journal Article

    Kuba, M. G.; Xu, B.; D’Angelo, S. P.; Rosenbaum, E.; Plitas, G.; Ross, D. S.; Brogi, E.; Antonescu, C. R.
    Histopathology (2021)

    Fulltext@MSK | Save
  • Gastrointestinal stromal tumors with BRAF gene fusions. A report of two cases showing low or absent KIT expression resulting in diagnostic pitfalls
    Journal Article

    Torrence, D.; Xie, Z.; Zhang, L.; Chi, P.; Antonescu, C. R.
    Genes Chromosomes and Cancer (2021)

    Fulltext@MSK | Save
  • Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: A randomized, open-label phase III study
    Journal Article

    Kang, Y. K.; George, S.; Jones, R. L.; Rutkowski, P.; Shen, L.; Mir, O.; Patel, S.; Zhou, Y.; von Mehren, M.; Hohenberger, P.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Association of combination of conformation-specific KIT inhibitors with clinical benefit in patients with refractory gastrointestinal stromal tumors: A phase 1b/2a nonrandomized clinical trial
    Journal Article

    Wagner, A. J.; Severson, P. L.; Shields, A. F.; Patnaik, A.; Chugh, R.; Tinoco, G.; Wu, G.; Nespi, M.; Lin, J.; Zhang, Y.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save